M K Proteins Q1 FY27 Results: Revenue Flat at Rs 115 Crore, PAT Halves to Rs 1 Crore
- August 14, 2026
- Posted by: Lakshit Sharma
- Category: Market
M K Proteins Q1 FY27: Revenue Rs 115 Cr (+0.19% YoY). PAT Rs 1 Cr (-60.65%). Gross profit Rs 2 Cr vs Rs 5 Cr (-56.22%). Standalone. CMP Rs 4.17 on Aug 13.
Quick Answer
M K Proteins reported a weak Q1 FY27 with standalone revenue essentially flat at Rs 115 crore, while PAT nearly halved to Rs 1 crore from Rs 3 crore in Q1 FY26 and gross profit fell 56% from Rs 5 crore to Rs 2 crore. M K Proteins Q1 FY27 results reflect significant gross margin compression in the protein products business, likely from elevated raw material costs for soyabean or other oilseed inputs.
M K Proteins Q1 FY27 results showed the standalone company reporting revenue of Rs 115 crore, essentially flat at +0.19% from Rs 114 crore in Q1 FY26. The soyabean processing and protein products company maintained its revenue scale but saw profitability deteriorate significantly due to raw material cost dynamics.
The M K Proteins Q1 FY27 results showed gross profit falling 56.22% from Rs 5 crore to Rs 2 crore on flat revenue, indicating that soyabean or protein input costs rose materially relative to selling prices for processed protein products, soya meal, and related outputs. PAT nearly halved from Rs 3 crore to Rs 1 crore.
Click Here – Get Free Investment Predictions
M K Proteins Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Crore) | Q1 FY26 (Rs Crore) | YoY Change |
|---|---|---|---|
| Revenue | 115.00 | 114.00 | +0.19% |
| Gross Profit | 2.00 | 5.00 | -56.22% |
| Net Profit / PAT | 1.00 | 3.00 | -60.65% |
M K Proteins Q1 FY27 Performance Analysis
Use the Univest Screener to track M K Proteins live financials and Q1 FY27 results
M K Proteins Q1 FY27 results reveal a sharp gross margin compression on flat revenue — a classic oilseed processing margin cycle challenge. Gross profit falling from Rs 5 crore to Rs 2 crore on Rs 115 crore revenue means gross margin contracted from 4.4% to 1.7%, driven by the spread between soyabean procurement costs and protein product realisations narrowing significantly.
The parallel between M K Proteins’ Q1 FY27 results and Ajanta Soya’s Q1 FY26 performance is instructive. Both are oilseed processing companies where profitability is determined by the input-output spread (crush margin). When soyabean prices are high relative to oil and meal realisations, margins compress — which appears to be what happened to M K Proteins in Q1 FY27.
PAT at Rs 1 crore in M K Proteins Q1 FY27 results, down 61% from Rs 3 crore, shows that the gross profit collapse has significantly impacted net earnings. The company retained some profitability due to low overhead costs, but the margin compression is severe on Rs 115 crore revenue.
Recovery for M K Proteins will depend on a reversal in soyabean crush margins — either from lower procurement costs or better protein product realisations. Given the cyclical nature of these margins, Q2 and Q3 FY27 could see improvement if global and domestic oilseed markets rebalance.
Key Business Factors in Q1 FY27
Soyabean Crush Margin Compression
The gross profit decline in M K Proteins Q1 FY27 results from Rs 5 crore to Rs 2 crore on flat revenue reflects adverse soyabean crush margins. When soyabean procurement prices rise or protein product/meal selling prices fall, the processing spread narrows, directly compressing gross profit.
Oilseed Price Volatility
Soyabean and protein product prices are influenced by global oilseed supply, South American crop production, and India’s import duty policies on edible oils. Any disruption in supply or policy change can rapidly alter the crush margin economics visible in M K Proteins Q1 FY27 results.
Revenue Scale Without Margin Recovery
The stable revenue at Rs 115 crore in M K Proteins Q1 FY27 results indicates maintained processing volumes, but the margin collapse means the company is earning much less per tonne of processing activity. Maintaining volumes while margins recover will support the earnings recovery.
Dividend Details
M K Proteins has not declared any dividend for Q1 FY27. The significant PAT decline in the quarter reduces the company’s immediate dividend capacity, and the board is likely focused on margins recovery.
FY27 Outlook
The FY27 outlook for M K Proteins depends on soyabean crush margin recovery. If the Q1 FY27 margin compression reflects temporary factors such as elevated domestic soyabean prices ahead of the new crop season, margins should improve as fresh soyabean supply arrives in Q2 and Q3 FY27.
The structural demand for soya protein products from the food processing, animal feed, and aquaculture sectors provides a stable revenue backdrop. Margin recovery rather than revenue growth will be the primary driver of PAT improvement from M K Proteins Q1 FY27 results.
M K Proteins Stock Performance
Download the Univest iOS App or Univest Android App to track M K Proteins share price live and stay updated on quarterly results.
M K Proteins shares traded at Rs 4.17 on August 13, 2026, down 0.24% on the day. The penny-stock price reflects the thin and cyclically variable margins of the soyabean processing business, consistent with the gross profit compression visible in Q1 FY27 results.
Key Risks
Cyclical Margin Volatility
Soyabean crush margins can swing dramatically within a single quarter based on global crop news, currency movements, and domestic demand patterns. M K Proteins Q1 FY27 results already show a severe margin cycle, and the risk of further compression or extended weakness is real.
Import Price Competition
India imports edible oils when domestic prices are high. Any large-scale import of cheaper edible oils could depress domestic soya oil prices, narrowing crush margins for M K Proteins beyond the Q1 FY27 results level.
Working Capital and Financing Risk
Oilseed processors typically carry large inventories of raw soyabean and work-in-progress. Any financing cost increase or procurement price spike without corresponding selling price improvement adds to the financial pressure visible in M K Proteins Q1 FY27 results.
Conclusion
M K Proteins Q1 FY27 results show the impact of soyabean crush margin compression, with gross profit falling 56% from Rs 5 crore to Rs 2 crore and PAT nearly halving to Rs 1 crore on flat revenue of Rs 115 crore. The cyclical nature of oilseed processing margins is the central determinant of this company’s quarterly earnings.
Margin recovery as soyabean prices normalise through FY27 is the key catalyst for improvement from M K Proteins Q1 FY27 results. Investors should track soyabean and edible oil commodity price trends alongside the company’s results. Consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on M K Proteins Q1 FY27 Results
When were M K Proteins Q1 FY27 results announced?
Ans. M K Proteins Q1 FY27 results were announced on August 13, 2026, covering the April to June 2026 quarter on a standalone basis.
What was M K Proteins’ revenue in Q1 FY27?
Ans. M K Proteins reported standalone revenue of Rs 115 crore in Q1 FY27, essentially flat at +0.19% from Rs 114 crore in Q1 FY26.
What was M K Proteins’ PAT in Q1 FY27?
Ans. M K Proteins’ net profit (PAT) was Rs 1 crore in Q1 FY27, down 60.65% from Rs 3 crore in Q1 FY26.
Why did M K Proteins’ gross profit fall 56% on flat revenue in Q1 FY27?
Ans. M K Proteins Q1 FY27 results show gross profit falling from Rs 5 crore to Rs 2 crore as soyabean crush margins compressed on elevated raw soyabean procurement costs relative to protein product and soya meal selling prices.
Did M K Proteins declare a dividend for Q1 FY27?
Ans. M K Proteins has not declared a dividend for Q1 FY27 given the significant PAT decline.
What is the outlook for M K Proteins after Q1 FY27 results?
Ans. The FY27 outlook depends on soyabean crush margin recovery as new crop supply arrives. Commodity price normalisation is the key catalyst for earnings improvement.
Is M K Proteins a good investment after Q1 FY27 results?
Ans. M K Proteins Q1 FY27 results show cyclical margin compression. Investors should track crush margin trends and assess commodity cycle positioning before investing. Consult a SEBI-registered advisor.